Arvinas Q2 2026 earnings: Licensing revenue drives a return to profit

Arvinas (Nasdaq: ARVN) reported Q2 2026 revenue of $249.7 million, up from $22.4 million a year earlier, while diluted EPS swung to $2.58 from a loss of $0.84. The turnaround was driven largely by Pfizer collaboration revenue, the Rigel license agreement, and a $50.0 million milestone tied to FDA approval of VEPPANU. Cash, cash equivalents, and marketable securities totaled $567.9 million at June 30, 2026.

Core financial results

Arvinas moved from an operating loss to a profit as revenue increased by $227.3 million and total operating expenses declined by $8.3 million. The expense reduction primarily came from lower R&D spending, partly offset by $9.0 million of new license-revenue costs associated with VEPPANU’s approval and the Rigel agreement.

All figures below are GAAP except per-share data.

The $16.0 million reduction in GAAP R&D expense primarily reflected an $11.0 million decline in compensation and related personnel costs and a $3.2 million reduction in external expenses. Lower spending on vepdegestrant was partly offset by increased investment in ARV-806, ARV-027, and ARV-393.

GAAP G&A expense declined modestly as lower personnel, infrastructure, and commercial-development costs outweighed a $4.2 million increase in professional fees. On a non-GAAP basis, which excludes restructuring and stock-based compensation, R&D expense fell to $51.4 million from $59.5 million, while G&A expense edged up to $18.4 million from $18.1 million.

Business and pipeline performance

VEPPANU received FDA approval for eligible adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, marking the first FDA approval of a PROTAC therapy. Arvinas and Pfizer subsequently licensed exclusive global development, manufacturing, and commercialization rights to Rigel Pharmaceuticals, and VEPPANU was added to the NCCN breast cancer guidelines as a Category 2A treatment option for the specified patient group.

Beyond VEPPANU, Arvinas is preparing several Phase 1 data releases and one new clinical-trial launch.

ARV-393’s reported activity remains preliminary, and the company did not provide response counts or durability data. Arvinas also presented preclinical pan-KRAS degrader results in pancreatic, colorectal, and lung cancer models, but no clinical timeline was disclosed for that program.

License accounting created profit while cash still declined

The revenue increase was concentrated in collaboration and licensing events rather than product sales. Arvinas recognized $112.6 million from its original vepdegestrant collaboration with Pfizer, primarily reflecting recognition of remaining deferred revenue after entering the Rigel agreement. It also recorded $62.5 million from the Rigel license and a $50.0 million development milestone following VEPPANU’s FDA approval.

This accounting-driven revenue recognition produced a Q2 profit, but it did not translate dollar-for-dollar into current-period cash. For the first six months of 2026, Arvinas reported $111.8 million of net income while using $114.3 million of cash in operations, with the latter figure net of $35.0 million received under the Rigel agreement.

The balance-sheet data show the extent of the cash decline and the company’s limited debt burden.

Financial guidance

Based on its current operating plan, Arvinas believes its June 30 cash resources can fund planned operating expenses and capital expenditures into the second half of 2028. The company did not provide revenue or earnings guidance.

The runway depends on the current spending plan and therefore remains sensitive to clinical-trial expansion, partnership activity, and the timing of pipeline development.

Recent insider transactions

The supplied insider dataset reports 555,552 shares purchased across 13 transactions and 126,026 shares sold across 18 transactions during the past six months, resulting in net purchases of 429,526 shares. Total insider holdings were listed at 5.1 million shares, with net purchases equal to 9.20% of those holdings; the data do not establish that all reported purchases were open-market transactions.

The 10 latest reported entries consisted of six director stock awards and four officer sales. The source did not provide share counts for these individual entries.

Risks investors need to watch

• Transaction-driven revenue may remain uneven. Q2’s profit depended heavily on deferred revenue recognition, licensing income, and an approval milestone, making the quarter less representative of ongoing operating cash generation.
• Commercial execution now depends on Rigel. Rigel holds exclusive global rights to develop, manufacture, and commercialize VEPPANU, so future product execution depends on the licensee’s performance.
• Upcoming pipeline evidence is still early-stage. ARV-393 activity was preliminary, while ARV-102, ARV-027, ARV-6723, and ARV-806 remain in Phase 1 or preclinical development.
• Cash consumption remains significant. Arvinas used $114.3 million in operating cash during the first half despite receiving $35.0 million from Rigel. The projected runway assumes the current operating plan.
• Further ARV-806 development requires a licensing strategy. Arvinas plans to seek an out-licensing agreement for additional trials beyond the current dose-escalation work.

Summary

Arvinas’ Q2 2026 profit reversal was primarily the result of VEPPANU-related collaboration, licensing, and milestone revenue, supported by lower R&D spending. The next operating tests are Rigel’s execution with the newly approved product, upcoming Phase 1 data across several programs, and whether Arvinas can maintain its planned cash runway while advancing the pipeline.